Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;47(5):153-155.
doi: 10.18773/austprescr.2024.039.

Immune checkpoint inhibitors and immune-related adverse events

Winston Naidoo  1   2   3 , Katharine Cuff  1   2   3 , Marissa Ryan  1   2   3
Affiliations
Review

Immune checkpoint inhibitors and immune-related adverse events

Winston Naidoo et al. Aust Prescr. 2024 Oct.
No abstract available

Keywords: adverse drug reactions; immune checkpoint inhibitors; immune-related adverse events; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none declared

Figures

Figure 1
Figure 1
Manifestations of immune-related adverse events that are possible with immune checkpoint inhibitors
See this image and copyright information in PMC

References

    1. Esfahani K, Meti N, Miller WH, Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ 2019;191:E40-6. 10.1503/cmaj.180870 - DOI - PMC - PubMed
    1. Cancer Care Ontario. Clinical Practice Guideline: Immune Checkpoint Inhibitor Toxicity Management. 2018. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/52976 [cited 2024 Aug 12]
    1. Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 2021;32:917-25. 10.1016/j.annonc.2021.03.204 - DOI - PubMed
    1. Nakai Y, Otsuka T, Inoue T, Nawa T, Hatano K, Yamamoto Y, et al. Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer. IJU Case Rep 2021;4:326-9. 10.1002/iju5.12338 - DOI - PMC - PubMed
    1. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80. 10.1038/s41571-019-0218-0 - DOI - PubMed

Further reading

    1. Ardolino L, Joshua A. Immune checkpoint inhibitors in malignancy. Aust Prescr 2019;42:62-7. 10.18773/austprescr.2019.012 - DOI - PMC - PubMed
    1. Cancer Care Ontario. Clinical Practice Guideline: Immune Checkpoint Inhibitor Toxicity Management. 2018. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/52976 [cited 2024 Aug 12]
    1. Cancer Institute NSW. Management of immune-related adverse events (irAEs). eviQ Cancer Treatments Online; 2022. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-mana... [cited 2024 Feb 11]
    1. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol 2021;39:4073-126. 10.1200/JCO.21.01440 - DOI - PubMed
    1. Yeoh HL, Freilich K, Voskoboynik M, Moore M, Andrews MC, Shackleton M, et al. Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice. Aust J Gen Pract 2023;52:378-85. 10.31128/AJGP-04-22-6408 - DOI - PubMed

LinkOut - more resources